Bio/Pharma Industry: Beyond Politics and the Pandemic
Representatives of industry organizations discuss crucial business, regulatory, science-based issues facing the industry.
The bio/pharma industry has demonstrated its R&D capabilities by accelerating development of vaccines and therapeutics to combat COVID-19. At the same time the industry faced intense scrutiny and political pressure. What are the short-, medium-, and long-term implications for bio/pharma development and manufacturing?
Panelists James Mayne, PhD, vice-president, Science & Regulatory Advocacy, PhRMA and Phyllis Arthur, vice-president for infectious diseases and diagnostics policy, Biotechnology Innovation Organization (BIO) shared insights during this Editors’ Series discussion moderated by editors of Pharmaceutical Technology and BioPharm International. The discussion was recorded on Nov. 11, 2020, during the 2020 Bio/Pharma Virtual Congress.
Shilpa Medicare Launches ‘Hybrid CDMO’ at DCAT Week 2025
March 17th 2025This model is being positioned by Shilpa as a dual approach that offers comprehensive discovery, clinical, and commercial outsourcing services in addition to commercially ready, “off-the-shelf” novel formulations for b2b licensing.
